NovaSom, Inc., the leader in obstructive sleep apnea (OSA) home testing and cost-containment solutions, has announced UnitedHealthcare plan  participants now have access to NovaSom home sleep testing services for sleep apnea diagnosis. Home sleep testing is a clinically equivalent alternative to in-facility sleep testing that can be performed from the comfort and privacy of a patient’s home, at a fraction of the cost.

NovaSom will utilize its field-based provider relations team to educate physicians on appropriate screening parameters that will help identify clinically appropriate patients for home sleep testing. NovaSom will also make available a customized, provider-friendly workflow process aligned with prior authorization requirements to assure cost-effective diagnosis and initiation of treatment through its proprietary       cloud-based MediTrack®System.   

“OSA is one of the most serious and under-diagnosed medical problems in the United States, generating significant medical expense. Currently, an estimated 95 percent of OSA testing is performed in sleep labs, though research shows home sleep testing is clinically appropriate for up to 80 percent of patients,” said Richard Hassett, MD, CEO, NovaSom.“Patients and primary care physicians prefer the convenience, privacy,       easy-access, accuracy and cost savings associated with NovaSom’s home sleep tests. We are pleased to partner with UnitedHealthcare, expanding  our industry-leading national payer relationships and bringing  convenient, affordable home testing to OSA sufferers nationwide.”   

NovaSom is the industry leader in home sleep testing for OSA, with the       first FDA-cleared device and over 10 years of experience in home sleep diagnostics. NovaSom’s home sleep testing technology monitors the five parameters recommended by the American Academy of Sleep Medicine (AASM) to diagnose OSA, and has been proven clinically equivalent to sleep lab studies in two peer-reviewed clinical publications. NovaSom is fully  accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center and is CMS approved as an Independent Diagnostic Testing Facility.

Obstructive Sleep Apnea (OSA) affects an estimated 18 million Americans. However, a startling 85 percent of sufferers are undiagnosed and  untreated, generating significant clinical complications and medical  expense for patients and the healthcare system. Nearly half of all OSA  patients also suffer from one or more serious health conditions such as diabetes, hypertension or heart failure that is either aggravated or  caused by OSA. Treating OSA reduces medical expenses, improves patient  quality of life and lowers associated health risks.

Related Posts with Thumbnails

Tagged with:

Filed under: Home Test DevicesObstructive Sleep ApneaSleepSleep ApneaSleep Apnea AwarenessSleep Apnea DevicesSleep Apnea DiagnosisSleep Apnea EquipmentsSleep Apnea EventsSleep Apnea MarketsSleep Apnea NewsSleep Apnea TestSleep Apnea TreatmentSleep CenterSleep DisordersSleep LabSleep ProblemsSleep Study

Like this post? Subscribe to my RSS feed and get loads more!